Revvity, Inc 8-K, filed Nov 3, 2026
Revvity, Inc. (RVTY)
8-K
2026-11-03
For: 2026-11-03
View Original
Added on
November 03, 2026
About this 8-K
Revvity, Inc filed this 8-K on November 3, 2026.
Revvity reported third-quarter revenue of $729 million and EPS from continuing operations of $0.56, raised 2026 pro forma guidance to $2.86 billion revenue and $5.40-$5.45 adjusted EPS, and agreed to sell its China immunodiagnostics assets for up to $200 million. AI summary
Items reported
- Item 2.02: Financial results
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2026
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: (781 ) 663-6900
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |||||||||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On November 3, 2026 , Revvity, Inc. (the “Company”) announced its financial results for the third quarter ended October 4, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01. Other Events
Exhibit 99.2 to the Current Report on Form 8-K sets forth the unaudited pro forma condensed consolidated financial statements to present the pro forma financial position and results of operations of the Company and its Subsidiaries based upon historical financial information after giving effect to the probable sale of substantially all of the assets related to the Company’s Immunodiagnostics business in China (“China IDX”) pursuant to a definitive agreement signed on July 31, 2026. The agreement provides for the sale of China IDX for up to $200 million, subject to adjustments and satisfaction of conditions. Management believes it is probable the transaction will close by the end of 2027 and therefore has included the unaudited pro forma condensed consolidated financial statements herein.
Cautionary Statement Concerning Forward-Looking Statements
Certain statements made herein contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the anticipated sale of substantially all of the assets of China IDX. Words such as “believes” and similar expressions are intended to identify forward-looking statements. Such statements are based on the Company’s current expectations and no assurances can be given that these expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation, the Company’s ability to execute acquisitions and divestitures and other factors which are described under the caption “Risk Factors” in the Company’s most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”). The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits
(b) Pro Forma Financial Information
The unaudited pro forma condensed financial statements of the Company, giving effect to the probable sale of substantially all of the assets related to China IDX, are included as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated by reference herein.
(d) Exhibits
EXHIBIT INDEX
| Exhibit No. | Description | |||||||||||||
| 99.1* | ||||||||||||||
| 99.2 | ||||||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL) | |||||||||||||
* This exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REVVITY, INC. | |||||
Date: | By: /s/ Maxwell Krakowiak Maxwell Krakowiak Senior Vice President and Chief Financial Officer | ||||
FOR IMMEDIATE RELEASE
November 3, 2026
Revvity Announces Financial Results for the Third Quarter of 2026
•Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth
•GAAP EPS from continuing operations of $0.56; adjusted EPS from continuing operations of $1.38; GAAP pro forma EPS from continuing operations of $0.60; pro forma adjusted EPS from continuing operations of $1.37
•Raises full year guidance
•Investor Day to be held November 13, 2026
WALTHAM, Mass. -- Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 4, 2026.
The Company reported GAAP earnings per share from continuing operations of $0.56, as compared to $0.41 in the same period a year ago. Revenue for the quarter was $729 million, as compared to $699 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $95 million, as compared to $82 million for the same period a year ago. GAAP operating profit margin from continuing operations was 13.1% as a percentage of revenue, as compared to 11.7% in the same period a year ago.
Adjusted earnings per share from continuing operations for the quarter was $1.38, as compared to $1.18 in the same period a year ago. Adjusted operating income was $209 million, as compared to $182 million for the same period a year ago. Adjusted operating profit margin was 28.7% as a percentage of revenue, as compared to 26.1% in the same period a year ago.
As a reminder, the Company entered into a definitive agreement to divest its Immunodiagnostics business in China (“China IDX”), which represented approximately 6% of the Company’s total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. The Company is providing third quarter 2026 financial results on a reported and pro forma basis; forward-looking guidance is provided on a pro forma basis only and excludes China IDX.
Pro forma earnings per share from continuing operations for the quarter was $0.60, as compared to $0.40 in the same period a year ago. Pro forma revenue for the quarter was $710 million, as compared to $660 million in the same period a year ago. Pro forma operating income was $102 million, as compared to $77 million in the same period a year ago. Pro forma operating profit margin was 14.3% as a percentage of pro forma revenue, as compared to 11.7% in the same period a year ago.
On a pro forma adjusted basis, earnings per share for the quarter was $1.37, as compared to $1.13 in the same period a year ago. Pro forma adjusted operating income was $209 million, as compared to $172 million for the same period a year ago. Pro forma adjusted operating profit margin was 29.4% as a percentage of pro forma revenue, as compared to 26.0% in the same period a year ago.
Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.
“Our exceptional third quarter performance demonstrates the momentum building across Revvity, as broad-based growth and strong execution drove results meaningfully ahead of our expectations,” said Prahlad Singh, president and chief executive officer of Revvity. “With end market conditions continuing to improve, a strong pipeline of innovation, and the benefits of our transformation increasingly evident in our results, Revvity is extremely well positioned to capitalize on the opportunities ahead.”
Financial Overview by Reporting Segment
Life Sciences
•Third quarter 2026 revenue was $380 million, as compared to $343 million in the same period a year ago. Pro forma revenue increased 11% and pro forma organic revenue increased 9% as compared to the same period a year ago.
•Third quarter 2026 adjusted operating income was $119 million, as compared to $101 million in the same period a year ago. Adjusted operating profit margin was 31.5% as a percentage of revenue, as compared to 29.5% in the same period a year ago.
Diagnostics
•Third quarter 2026 revenue was $349 million, as compared to $356 million in the same period a year ago. Pro forma revenue increased 4% and pro forma organic revenue increased 5% as compared to the same period a year ago.
•Third quarter 2026 adjusted operating income was $104 million, as compared to $89 million in the same period a year ago. Adjusted operating profit margin was 29.9% as a percentage of revenue, as compared to 25.1% in the same period a year ago.
Full Year 2026 Guidance
For the full year 2026, on a pro forma basis, the Company forecasts total revenue of approximately $2.86 billion, pro forma organic revenue growth of approximately 5%, and pro forma adjusted earnings per share of $5.40-$5.45.
Guidance for the full year 2026 for pro forma organic revenue growth and pro forma adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.
Webcast Information
The Company will discuss its third quarter 2026 results and its outlook for business trends during a webcast on November 3, 2026, at 7:30 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.
Investor Day
Revvity will be hosting its 2026 Investor Day on Friday, November 13 beginning at 9:00 a.m. ET. Registration details can be found at ir.revvity.com. Presentations from members of Revvity’s senior management team will provide updates on the Company’s key business initiatives, operational achievements and financial outlook.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes”, “intends”, “anticipates”, “plans”, “expects”, “estimates”, “projects”, “forecasts”, “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) uncertainties related to the development and use of AI in our product offerings and internal operations; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) our failure to comply with data privacy and information security laws and regulations; (18) regulatory changes; (19) our failure to comply with healthcare industry regulations; (20) economic, political and other risks associated with foreign operations; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) significant fluctuations in our stock price; (24) reduction or elimination of dividends on our common stock; and (25) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
Revvity, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
| Three Months Ended October 4, 2026 | Three Months Ended September 28, 2025 | |||||||||||||||||||||||||
| (In thousands, except per share data) | As Reported | Pro Forma | As Reported | Pro Forma | ||||||||||||||||||||||
| Revenue | $ | 728,899 | $ | 709,606 | $ | 698,949 | $ | 660,451 | ||||||||||||||||||
| Cost of revenue | 310,320 | 301,251 | 324,345 | 302,094 | ||||||||||||||||||||||
| Selling, general and administrative expenses | 275,330 | 259,434 | 241,911 | 230,096 | ||||||||||||||||||||||
| Research and development expenses | 48,108 | 47,302 | 50,797 | 50,797 | ||||||||||||||||||||||
| Operating income from continuing operations | 95,141 | 101,619 | 81,896 | 77,464 | ||||||||||||||||||||||
| Interest income | (3,545) | (3,533) | (6,925) | (6,909) | ||||||||||||||||||||||
| Interest expense | 20,813 | 20,813 | 22,771 | 22,771 | ||||||||||||||||||||||
| Change in fair value of investments | (1,627) | (1,627) | 4,602 | 4,602 | ||||||||||||||||||||||
| Other expense, net | 1,817 | 3,722 | 5,763 | 5,088 | ||||||||||||||||||||||
| Income from continuing operations, before income taxes | 77,683 | 82,244 | 55,685 | 51,912 | ||||||||||||||||||||||
| Provision for income taxes | 15,062 | 14,868 | 8,464 | 6,574 | ||||||||||||||||||||||
| Income from continuing operations | 62,621 | 67,376 | 47,221 | 45,338 | ||||||||||||||||||||||
| Loss from discontinued operations | (322) | (322) | (569) | (569) | ||||||||||||||||||||||
| Net income | $ | 62,299 | $ | 67,054 | $ | 46,652 | $ | 44,769 | ||||||||||||||||||
| Diluted earnings per share: | ||||||||||||||||||||||||||
| Income from continuing operations | $ | 0.56 | $ | 0.60 | $ | 0.41 | $ | 0.40 | ||||||||||||||||||
| Loss from discontinued operations | (0.00) | (0.00) | (0.01) | (0.01) | ||||||||||||||||||||||
| Net income | $ | 0.56 | $ | 0.60 | $ | 0.40 | $ | 0.39 | ||||||||||||||||||
| Weighted average diluted shares of common stock outstanding | 111,826 | 111,826 | 115,463 | 115,463 | ||||||||||||||||||||||
| ABOVE PREPARED IN ACCORDANCE WITH GAAP | ||||||||||||||||||||||||||
Additional supplemental information(1): | ||||||||||||||||||||||||||
| (per share, continuing operations) | ||||||||||||||||||||||||||
| Three Months Ended October 4, 2026 | Three Months Ended September 28, 2025 | |||||||||||||||||||||||||
| As Reported | Pro Forma | As Reported | Pro Forma | |||||||||||||||||||||||
| GAAP EPS from continuing operations | $ | 0.56 | $ | 0.60 | $ | 0.41 | $ | 0.40 | ||||||||||||||||||
| Amortization of intangible assets | 0.76 | 0.70 | 0.73 | 0.68 | ||||||||||||||||||||||
| Purchase accounting adjustments | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||||||||||
| Acquisition and divestiture-related costs | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||||||||||
| Transformation costs | 0.01 | 0.01 | 0.04 | 0.04 | ||||||||||||||||||||||
| Change in fair value of investments | (0.01) | (0.01) | 0.04 | 0.04 | ||||||||||||||||||||||
| Significant litigation matters and settlements | — | — | 0.01 | 0.01 | ||||||||||||||||||||||
| Restructuring and other | 0.25 | 0.25 | 0.09 | 0.08 | ||||||||||||||||||||||
| Tax on above items | (0.18) | (0.17) | (0.17) | (0.16) | ||||||||||||||||||||||
| Significant tax items | — | — | 0.03 | 0.03 | ||||||||||||||||||||||
| Adjusted EPS from continuing operations | $ | 1.38 | $ | 1.37 | $ | 1.18 | $ | 1.13 | ||||||||||||||||||
| (1) amounts may not sum due to rounding | ||||||||||||||||||||||||||
Revvity, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
| Nine Months Ended October 4, 2026 | Nine Months Ended September 28, 2025 | |||||||||||||||||||||||||
| (In thousands, except per share data) | As Reported | Pro Forma | As Reported | Pro Forma | ||||||||||||||||||||||
| Revenue | $ | 2,169,705 | $ | 2,107,627 | $ | 2,083,995 | $ | 1,969,696 | ||||||||||||||||||
| Cost of revenue | 946,605 | 913,293 | 941,289 | 880,285 | ||||||||||||||||||||||
| Selling, general and administrative expenses | 807,788 | 764,949 | 740,156 | 749,811 | ||||||||||||||||||||||
| Research and development expenses | 154,969 | 153,986 | 157,664 | 157,664 | ||||||||||||||||||||||
| Operating income from continuing operations | 260,343 | 275,399 | 244,886 | 181,936 | ||||||||||||||||||||||
| Interest income | (15,108) | (15,068) | (25,351) | (25,304) | ||||||||||||||||||||||
| Interest expense | 68,521 | 68,521 | 68,672 | 68,672 | ||||||||||||||||||||||
| Change in fair value of investments | 7,828 | 7,828 | 3,484 | 3,484 | ||||||||||||||||||||||
| Other expense, net | 7,896 | 10,289 | 21,364 | 19,384 | ||||||||||||||||||||||
| Income from continuing operations, before income taxes | 191,206 | 203,829 | 176,717 | 115,700 | ||||||||||||||||||||||
| Provision for income taxes | 34,211 | 32,682 | 32,605 | 30,238 | ||||||||||||||||||||||
| Income from continuing operations | 156,995 | 171,147 | 144,112 | 85,462 | ||||||||||||||||||||||
| Loss from discontinued operations | (2,158) | (2,158) | (1,275) | (1,275) | ||||||||||||||||||||||
| Net income | $ | 154,837 | $ | 168,989 | $ | 142,837 | $ | 84,187 | ||||||||||||||||||
| Diluted earnings per share: | ||||||||||||||||||||||||||
| Income from continuing operations | $ | 1.40 | $ | 1.53 | $ | 1.22 | $ | 0.73 | ||||||||||||||||||
| Loss from discontinued operations | (0.02) | (0.02) | (0.01) | (0.01) | ||||||||||||||||||||||
| Net income | $ | 1.38 | $ | 1.51 | $ | 1.21 | $ | 0.72 | ||||||||||||||||||
| Weighted average diluted shares of common stock outstanding | 111,764 | 111,764 | 117,735 | 117,735 | ||||||||||||||||||||||
| ABOVE PREPARED IN ACCORDANCE WITH GAAP | ||||||||||||||||||||||||||
Additional supplemental information(1): | ||||||||||||||||||||||||||
| (per share, continuing operations) | ||||||||||||||||||||||||||
| Nine Months Ended October 4, 2026 | Nine Months Ended September 28, 2025 | |||||||||||||||||||||||||
| As Reported | Pro Forma | As Reported | Pro Forma | |||||||||||||||||||||||
| GAAP EPS from continuing operations | $ | 1.40 | $ | 1.53 | $ | 1.22 | $ | 0.73 | ||||||||||||||||||
| Amortization of intangible assets | 2.28 | 2.10 | 2.14 | 2.00 | ||||||||||||||||||||||
| Purchase accounting adjustments | 0.02 | 0.02 | 0.02 | 0.02 | ||||||||||||||||||||||
| Acquisition and divestiture-related costs | 0.01 | 0.01 | 0.02 | 0.02 | ||||||||||||||||||||||
| Transformation costs | 0.01 | 0.01 | 0.05 | 0.05 | ||||||||||||||||||||||
| Change in fair value of investments | 0.07 | 0.07 | 0.03 | 0.03 | ||||||||||||||||||||||
| Loss from probable dispositions | — | — | — | 0.40 | ||||||||||||||||||||||
| Significant litigation matters and settlements | 0.00 | 0.00 | 0.11 | 0.11 | ||||||||||||||||||||||
| Significant environmental matters | — | — | (0.01) | (0.01) | ||||||||||||||||||||||
| Disposition of businesses and assets, net | (0.05) | (0.05) | — | — | ||||||||||||||||||||||
| Mark to market on postretirement benefits | (0.02) | (0.02) | 0.04 | 0.04 | ||||||||||||||||||||||
| Restructuring and other | 0.67 | 0.65 | 0.21 | 0.20 | ||||||||||||||||||||||
| Tax on above items | (0.55) | (0.51) | (0.49) | (0.40) | ||||||||||||||||||||||
| Significant tax items | — | — | 0.03 | 0.03 | ||||||||||||||||||||||
| Adjusted EPS from continuing operations | $ | 3.85 | $ | 3.82 | $ | 3.37 | $ | 3.23 | ||||||||||||||||||
| (1) amounts may not sum due to rounding | ||||||||||||||||||||||||||
Revvity, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
| Three Months Ended October 4, 2026 | Three Months Ended September 28, 2025 | |||||||||||||||||||||||||
| (In thousands, except percentages) | As Reported | Pro Forma | As Reported | Pro Forma | ||||||||||||||||||||||
| Revenue and adjusted operating income | ||||||||||||||||||||||||||
| Revenue | $ | 728,899 | $ | 709,606 | $ | 698,949 | $ | 660,451 | ||||||||||||||||||
| Operating income from continuing operations | $ | 95,141 | $ | 101,619 | $ | 81,896 | $ | 77,464 | ||||||||||||||||||
| OP% | 13.1 | % | 14.3 | % | 11.7 | % | 11.7 | % | ||||||||||||||||||
| Amortization of intangible assets | 84,691 | 78,144 | 84,074 | 78,635 | ||||||||||||||||||||||
| Purchase accounting adjustments | 300 | 300 | 348 | 348 | ||||||||||||||||||||||
| Acquisition and divestiture-related costs | 70 | 70 | 284 | 284 | ||||||||||||||||||||||
| Transformation costs | 612 | 612 | 5,103 | 5,103 | ||||||||||||||||||||||
| Significant litigation matters and settlements | 150 | 150 | 785 | 785 | ||||||||||||||||||||||
| Restructuring and other | 28,357 | 27,952 | 9,926 | 9,376 | ||||||||||||||||||||||
| Adjusted operating income | $ | 209,321 | $ | 208,847 | $ | 182,416 | $ | 171,995 | ||||||||||||||||||
| OP% | 28.7 | % | 29.4 | % | 26.1 | % | 26.0 | % | ||||||||||||||||||
| Three Months Ended | ||||||||||||||||||||||||||
| October 4, 2026 | September 28, 2025 | |||||||||||||||||||||||||
| (In thousands, except percentages) | ||||||||||||||||||||||||||
| Segment revenue: | ||||||||||||||||||||||||||
| Life Sciences | $ | 379,586 | $ | 342,822 | ||||||||||||||||||||||
| Diagnostics | 349,313 | 356,127 | ||||||||||||||||||||||||
| Segment revenue | 728,899 | 698,949 | ||||||||||||||||||||||||
| Segment operating income: | ||||||||||||||||||||||||||
| Life Sciences | $ | 119,469 | $ | 101,048 | ||||||||||||||||||||||
| 31.5 | % | 29.5 | % | |||||||||||||||||||||||
| Diagnostics | 104,313 | 89,376 | ||||||||||||||||||||||||
| 29.9 | % | 25.1 | % | |||||||||||||||||||||||
| Segment operating income | 223,782 | 190,424 | ||||||||||||||||||||||||
| Corporate | (14,461) | (8,008) | ||||||||||||||||||||||||
| Adjusted operating income | 209,321 | 182,416 | ||||||||||||||||||||||||
| Amortization of intangible assets | (84,691) | (84,074) | ||||||||||||||||||||||||
| Purchase accounting adjustments | (300) | (348) | ||||||||||||||||||||||||
| Acquisition and divestiture-related costs | (70) | (284) | ||||||||||||||||||||||||
| Transformation costs | (612) | (5,103) | ||||||||||||||||||||||||
| Significant litigation matters and settlements | (150) | (785) | ||||||||||||||||||||||||
| Restructuring and other | (28,357) | (9,926) | ||||||||||||||||||||||||
| Reported operating income from continuing operations | $ | 95,141 | $ | 81,896 | ||||||||||||||||||||||
| REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP | ||||||||||||||||||||||||||
Revvity, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
| Nine Months Ended October 4, 2026 | Nine Months Ended September 28, 2025 | |||||||||||||||||||||||||
| (In thousands, except percentages) | As Reported | Pro Forma | As Reported | Pro Forma | ||||||||||||||||||||||
| Revenue and adjusted operating income | ||||||||||||||||||||||||||
| Revenue | $ | 2,169,705 | $ | 2,107,627 | $ | 2,083,995 | $ | 1,969,696 | ||||||||||||||||||
| Operating income from continuing operations | 260,343 | 275,399 | 244,886 | 181,936 | ||||||||||||||||||||||
| OP% | 12.0 | % | 13.1 | % | 11.8 | % | 9.2 | % | ||||||||||||||||||
| Amortization of intangible assets | 254,643 | 235,236 | 252,063 | 235,881 | ||||||||||||||||||||||
| Purchase accounting adjustments | 2,307 | 2,307 | 2,349 | 2,349 | ||||||||||||||||||||||
| Acquisition and divestiture-related costs | 456 | 394 | 2,950 | 2,950 | ||||||||||||||||||||||
| Disposition of businesses and assets, net | (5,074) | (5,074) | — | — | ||||||||||||||||||||||
| Transformation costs | 671 | 670 | 6,226 | 6,226 | ||||||||||||||||||||||
| Loss from probable dispositions | — | — | — | 46,809 | ||||||||||||||||||||||
| Significant litigation matters and settlements | 298 | 298 | 12,495 | 12,495 | ||||||||||||||||||||||
| Significant environmental matters | — | — | (1,208) | (1,208) | ||||||||||||||||||||||
| Restructuring and other | 74,540 | 73,149 | 24,368 | 23,818 | ||||||||||||||||||||||
| Adjusted operating income | $ | 588,184 | $ | 582,379 | $ | 544,129 | $ | 511,256 | ||||||||||||||||||
| OP% | 27.1 | % | 27.6 | % | 26.1 | % | 26.0 | % | ||||||||||||||||||
| Nine Months Ended | ||||||||||||||||||||||||||
| October 4, 2026 | September 28, 2025 | |||||||||||||||||||||||||
| (In thousands, except percentages) | ||||||||||||||||||||||||||
| Segment revenue: | ||||||||||||||||||||||||||
| Life Sciences | $ | 1,100,130 | $ | 1,049,115 | ||||||||||||||||||||||
| Diagnostics | 1,069,575 | 1,034,880 | ||||||||||||||||||||||||
| Segment revenue | 2,169,705 | 2,083,995 | ||||||||||||||||||||||||
| Segment operating income: | ||||||||||||||||||||||||||
| Life Sciences | $ | 334,982 | $ | 322,228 | ||||||||||||||||||||||
| 30.4 | % | 30.7 | % | |||||||||||||||||||||||
| Diagnostics | 293,301 | 252,813 | ||||||||||||||||||||||||
| 27.4 | % | 24.4 | % | |||||||||||||||||||||||
| Segment operating income | 628,283 | 575,041 | ||||||||||||||||||||||||
| Corporate | (40,099) | (30,912) | ||||||||||||||||||||||||
| Adjusted operating income | 588,184 | 544,129 | ||||||||||||||||||||||||
| Amortization of intangible assets | (254,643) | (252,063) | ||||||||||||||||||||||||
| Purchase accounting adjustments | (2,307) | (2,349) | ||||||||||||||||||||||||
| Acquisition and divestiture-related costs | (456) | (2,950) | ||||||||||||||||||||||||
| Disposition of businesses and assets, net | 5,074 | — | ||||||||||||||||||||||||
| Transformation costs | (671) | (6,226) | ||||||||||||||||||||||||
| Significant litigation matters and settlements | (298) | (12,495) | ||||||||||||||||||||||||
| Significant environmental matters | — | 1,208 | ||||||||||||||||||||||||
| Restructuring and other | (74,540) | (24,368) | ||||||||||||||||||||||||
| Reported operating income from continuing operations | $ | 260,343 | $ | 244,886 | ||||||||||||||||||||||
| REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP | ||||||||||||||||||||||||||
Revvity, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
| (In thousands) | October 4, 2026 | December 28, 2025 | |||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 592,799 | $ | 919,860 | |||||||
| Accounts receivable, net | 687,328 | 744,671 | |||||||||
| Inventories, net | 388,850 | 379,497 | |||||||||
| Other current assets | 192,414 | 195,719 | |||||||||
| Total current assets | 1,861,391 | 2,239,747 | |||||||||
| Property, plant and equipment, net | 450,870 | 479,249 | |||||||||
| Operating lease right-of-use assets, net | 146,823 | 165,439 | |||||||||
| Intangible assets, net | 2,137,551 | 2,347,003 | |||||||||
| Goodwill | 6,588,150 | 6,613,493 | |||||||||
| Other assets, net | 305,561 | 323,480 | |||||||||
| Total assets | $ | 11,490,346 | $ | 12,168,411 | |||||||
| Current liabilities: | |||||||||||
| Current portion of long-term debt | $ | — | $ | 588,828 | |||||||
| Accounts payable | 163,271 | 185,464 | |||||||||
| Accrued expenses and other current liabilities | 538,206 | 556,954 | |||||||||
| Total current liabilities | 701,477 | 1,331,246 | |||||||||
| Long-term debt | 2,634,062 | 2,631,236 | |||||||||
| Long-term liabilities | 752,731 | 807,461 | |||||||||
| Operating lease liabilities | 130,970 | 148,108 | |||||||||
| Total liabilities | 4,219,240 | 4,918,051 | |||||||||
| Total stockholders' equity | 7,271,106 | 7,250,360 | |||||||||
| Total liabilities and stockholders' equity | $ | 11,490,346 | $ | 12,168,411 | |||||||
| PREPARED IN ACCORDANCE WITH GAAP | |||||||||||
Revvity, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| (In thousands) | October 4, 2026 | September 28, 2025 | October 4, 2026 | September 28, 2025 | |||||||||||||||||||
| Operating activities: | |||||||||||||||||||||||
| Net income | $ | 62,299 | $ | 46,652 | $ | 154,837 | $ | 142,837 | |||||||||||||||
| Loss from discontinued operations, net of income taxes | 322 | 569 | 2,158 | 1,275 | |||||||||||||||||||
| Income from continuing operations | 62,621 | 47,221 | 156,995 | 144,112 | |||||||||||||||||||
| Adjustments to reconcile income from continuing operations to net cash provided by continuing operations: | |||||||||||||||||||||||
| Stock-based compensation | 9,752 | 9,054 | 29,198 | 26,918 | |||||||||||||||||||
| Restructuring and other | 28,357 | 9,926 | 74,540 | 24,368 | |||||||||||||||||||
| Depreciation and amortization | 102,918 | 102,061 | 310,013 | 302,261 | |||||||||||||||||||
| Change in fair value of contingent consideration | 60 | 107 | 1,587 | (59) | |||||||||||||||||||
| Amortization of deferred debt financing costs and accretion of discounts | 1,007 | 1,240 | 3,447 | 3,560 | |||||||||||||||||||
| Change in fair value of investments | (1,627) | 4,602 | 7,828 | 3,484 | |||||||||||||||||||
| Unrealized foreign exchange loss | — | 82 | 186 | 222 | |||||||||||||||||||
| Gains on disposition of businesses and assets, net | — | — | (5,074) | — | |||||||||||||||||||
| Changes in assets and liabilities which (used) provided cash: | |||||||||||||||||||||||
| Accounts receivable, net | 22,489 | (19,742) | 66,405 | (41,643) | |||||||||||||||||||
| Inventories, net | (13,354) | 6,851 | (18,132) | 12,493 | |||||||||||||||||||
| Accounts payable | (1,585) | (3,008) | (19,648) | 270 | |||||||||||||||||||
| Accrued expenses and other | (43,934) | (19,813) | (122,811) | (68,990) | |||||||||||||||||||
| Net cash provided by operating activities of continuing operations | 166,704 | 138,581 | 484,534 | 406,996 | |||||||||||||||||||
| Net cash used in operating activities of discontinued operations | — | (81) | (10,657) | (6,023) | |||||||||||||||||||
| Net cash provided by operating activities | 166,704 | 138,500 | 473,877 | 400,973 | |||||||||||||||||||
| Investing activities: | |||||||||||||||||||||||
| Capital expenditures | (14,346) | (18,501) | (45,194) | (53,351) | |||||||||||||||||||
| Purchases of investments and notes receivables | (1,250) | (29) | (4,811) | (29) | |||||||||||||||||||
| Proceeds from investments and notes receivables | — | — | 7,496 | — | |||||||||||||||||||
| Proceeds from dispositions of property, plant and equipment | — | — | 12,039 | — | |||||||||||||||||||
| Proceeds from disposition of businesses and assets | — | — | 158 | 229 | |||||||||||||||||||
| Cash paid for acquisitions, net of cash acquired | — | — | (67,061) | — | |||||||||||||||||||
| Net cash used in investing activities of continuing operations | (15,596) | (18,530) | (97,373) | (53,151) | |||||||||||||||||||
| Net cash provided by investing activities of discontinued operations | — | 37,500 | — | 56,250 | |||||||||||||||||||
| Net cash (used in) provided by investing activities | (15,596) | 18,970 | (97,373) | 3,099 | |||||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| (In thousands) | October 4, 2026 | September 28, 2025 | October 4, 2026 | September 28, 2025 | |||||||||||||||||||
| Financing Activities: | |||||||||||||||||||||||
| Payments on borrowings | $ | (25,000) | $ | — | $ | (25,000) | $ | — | |||||||||||||||
| Proceeds from borrowings | 25,000 | — | 25,000 | — | |||||||||||||||||||
| Payments of senior unsecured notes | (571,193) | — | (571,193) | — | |||||||||||||||||||
| Payments of debt financing costs | — | — | — | (2,474) | |||||||||||||||||||
| Payments on other credit facilities | — | (55) | — | (158) | |||||||||||||||||||
| Payments for acquisition-related contingent consideration | — | (1,860) | (350) | (3,838) | |||||||||||||||||||
| Proceeds from issuance of common stock under stock plans | 3,485 | — | 9,922 | 2,632 | |||||||||||||||||||
| Purchases of common stock | (95) | (205,029) | (102,583) | (652,530) | |||||||||||||||||||
| Dividends paid | (7,811) | (8,130) | (23,465) | (24,845) | |||||||||||||||||||
| Net cash used in financing activities | (575,614) | (215,074) | (687,669) | (681,213) | |||||||||||||||||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (5,709) | (2,811) | (15,899) | 45,264 | |||||||||||||||||||
| Net decrease in cash, cash equivalents, and restricted cash | (430,215) | (60,415) | (327,064) | (231,877) | |||||||||||||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 1,024,181 | 992,990 | 921,030 | 1,164,452 | |||||||||||||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 593,966 | $ | 932,575 | $ | 593,966 | $ | 932,575 | |||||||||||||||
| Supplemental disclosure of cash flow information: | |||||||||||||||||||||||
| Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows: | |||||||||||||||||||||||
| Cash and cash equivalents | $ | 592,799 | $ | 931,386 | $ | 592,799 | $ | 931,386 | |||||||||||||||
| Restricted cash included in other current assets | 600 | 1,189 | 600 | 1,189 | |||||||||||||||||||
| Restricted cash included in other assets | 567 | — | 567 | — | |||||||||||||||||||
| Total cash, cash equivalents and restricted cash | $ | 593,966 | $ | 932,575 | $ | 593,966 | $ | 932,575 | |||||||||||||||
| PREPARED IN ACCORDANCE WITH GAAP | |||||||||||||||||||||||
Revvity, Inc. and Subsidiaries
RECONCILIATION OF FINANCIAL METRICS (1)
| Continuing Operations | |||||||||||
| Three Months Ended | |||||||||||
| October 4, 2026 | |||||||||||
| Pro forma organic revenue growth: | |||||||||||
| Pro forma revenue growth from continuing operations | 7% | ||||||||||
| Less: effect of foreign exchange rates | -1% | ||||||||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 1% | ||||||||||
| Pro forma organic revenue growth from continuing operations | 7% | ||||||||||
| Life Sciences | |||||||||||
| Three Months Ended | |||||||||||
| October 4, 2026 | |||||||||||
| Pro forma organic revenue growth: | |||||||||||
| Pro forma revenue growth from continuing operations | 11% | ||||||||||
| Less: effect of foreign exchange rates | 0% | ||||||||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 2% | ||||||||||
| Pro forma organic revenue growth from continuing operations | 9% | ||||||||||
| Diagnostics | |||||||||||
| Three Months Ended | |||||||||||
| October 4, 2026 | |||||||||||
| Pro forma organic revenue growth: | |||||||||||
| Pro forma revenue growth from continuing operations | 4% | ||||||||||
| Less: effect of foreign exchange rates | -1% | ||||||||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0% | ||||||||||
| Pro forma organic revenue growth from continuing operations | 5% | ||||||||||
| (1) amounts may not sum due to rounding | |||||||||||
Revvity, Inc. and Subsidiaries
RECONCILIATION OF FINANCIAL METRICS (1)
| Continuing Operations | |||||||||||
| Nine Months Ended | |||||||||||
| October 4, 2026 | |||||||||||
| Pro forma organic revenue growth: | |||||||||||
| Pro forma revenue growth from continuing operations | 7% | ||||||||||
| Less: effect of foreign exchange rates | 1% | ||||||||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 1% | ||||||||||
| Pro forma organic revenue growth from continuing operations | 5% | ||||||||||
| Life Sciences | |||||||||||
| Nine Months Ended | |||||||||||
| October 4, 2026 | |||||||||||
| Pro forma organic revenue growth: | |||||||||||
| Pro forma revenue growth from continuing operations | 5% | ||||||||||
| Less: effect of foreign exchange rates | 1% | ||||||||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 1% | ||||||||||
| Pro forma organic revenue growth from continuing operations | 3% | ||||||||||
| Diagnostics | |||||||||||
| Nine Months Ended | |||||||||||
| October 4, 2026 | |||||||||||
| Pro forma organic revenue growth: | |||||||||||
| Pro forma revenue growth from continuing operations | 9% | ||||||||||
| Less: effect of foreign exchange rates | 1% | ||||||||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0% | ||||||||||
| Pro forma organic revenue growth from continuing operations | 8% | ||||||||||
| (1) amounts may not sum due to rounding | |||||||||||
Explanation of Non-GAAP Financial Measures
We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.
We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions, divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” or “organic growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.
We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions and asset impairments. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of revenue.
We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of revenue.
We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of revenue.
We use the term “adjusted net interest and other expense” to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of investments and debt extinguishment costs.
We use the term “adjusted operating income” to refer to GAAP operating income, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” and “adjusted operating margin” to refer to adjusted operating income as a percentage of revenue.
We use the term “free cash flow” to refer to net cash provided by (used in) operating activities of continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”).
We use the term “adjusted net income” to refer to GAAP income from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.
We use the term “adjusted earnings per share from continuing operations,” “adjusted earnings per share,” “adjusted EPS,” or “adjusted EPS from continuing operations” to refer to GAAP earnings per share from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.
We use the term “pro forma organic revenue” to refer to organic revenue excluding revenue from probable dispositions. We use the related term “pro forma organic revenue growth”, “pro forma organic revenue growth from continuing operations” or “pro forma organic growth” to refer to the measure of comparing current period pro forma organic revenue with the corresponding period of the prior year.
We use the term “pro forma adjusted gross margin” to refer to adjusted gross margin, excluding gross margin from probable dispositions. We use the related term “pro forma adjusted gross margin percentage” to refer to pro forma adjusted gross margin as a percentage of pro forma revenue.
We use the term “pro forma adjusted SG&A expense” to refer to adjusted SG&A expense, excluding SG&A expense from probable dispositions and gains(losses) on sale of probable dispositions. We use the related term “pro forma adjusted SG&A percentage” to refer to pro forma adjusted SG&A expense as a percentage of pro forma revenue.
We use the term “pro forma adjusted R&D expense” to refer to adjusted R&D expense, excluding R&D expense from probable dispositions. We use the related term “pro forma adjusted R&D percentage” to refer to pro forma adjusted R&D expense as a percentage of pro forma revenue.
We use the term “pro forma adjusted net interest and other expense” to refer to adjusted net interest and other expense, excluding net interest and expense from probable dispositions.
We use the term “pro forma adjusted operating income” to refer to adjusted operating income, excluding operating income from probable dispositions. We use the related terms “pro forma adjusted operating profit percentage,” “pro forma adjusted operating profit margin,” and “pro forma adjusted operating margin” to refer to pro forma adjusted operating income as a percentage of pro forma revenue.
We use the term “pro forma adjusted earnings per share from continuing operations,” “pro forma adjusted earnings per share,” “pro forma adjusted EPS,” or “pro forma adjusted EPS from continuing operations” to refer to adjusted earnings per share from continuing operations, excluding net income from probable dispositions and gains (losses) on sale of probable dispositions.
Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:
•Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
•Debt extinguishment costs—we incur costs and income related to the extinguishment of debt, including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
•Purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets, deferred revenue and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
•Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
•Transformation costs—transformation costs consist of external professional service costs related to transformation initiatives focused on business processes modernization, automation, and implementation of global systems to support the new Revvity Business Model. These costs are determined to be noncapitalizable in accordance with accounting standards. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
•Asset impairments—we incur expenses related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
•Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
•Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
•Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
•Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
•Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
•Impact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period’s foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
•Impact of significant tax events—we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
•Change in fair value of investments—we exclude the impact of changes in the value of investments. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
# # #
The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board’s Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, transformation costs, loss from probable dispositions, significant litigation matters and settlements, significant environmental charges, changes in the fair value of investments, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, and restructuring and other charges is calculated based on operational results and a blended jurisdictional tax rate, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on a blended jurisdictional tax rate currently in effect to determine our tax provision.
The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.
Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.
Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com
Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com
Exhibit 99.2
Revvity, Inc. and Subsidiaries
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The unaudited pro forma condensed consolidated financial statements presented herein have been prepared in accordance with Article 11 of Regulation S-X and are based upon the Company’s audited consolidated financial statements for the year ended December 28, 2025 and the unaudited consolidated financial statements for the nine months ended October 4, 2026 and certain assumptions, as set forth in the notes to unaudited pro forma condensed consolidated financial statements, that the Company believes are reasonable. On July 31, 2026, the Company entered into a definitive agreement to divest its Immunodiagnostics business in China (“China IDX”). The unaudited pro forma condensed consolidated balance sheet is presented as if the sale had been completed on October 4, 2026 and the unaudited pro forma condensed consolidated statements of operations are presented as if the sale had been completed on December 30, 2024. The pro forma adjustments presented herein are based on estimates and certain information that is currently available and may change as additional information becomes available. The unaudited pro forma condensed consolidated financial statements are not necessarily indicative of the results of operations or the financial position that would have resulted had the sale of China IDX been completed at the beginning of or as of the periods presented, nor is it indicative of the results of operations in future periods or the future financial position of the Company.
Revvity, Inc. and Subsidiaries
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
AS OF OCTOBER 4, 2026
| (In thousands) | Historical | Disposition and Pro Forma Adjustments | Pro Forma | ||||||||||||||
| Current assets: | |||||||||||||||||
| Cash and cash equivalents | $ | 592,799 | $ | 9,696 | (a), (b) | $ | 602,495 | ||||||||||
| Accounts receivable, net | 687,328 | (72,924) | (a) | 614,404 | |||||||||||||
| Inventories, net | 388,850 | (7,120) | (a) | 381,730 | |||||||||||||
| Other current assets | 192,414 | 45,182 | (a), (b) | 237,596 | |||||||||||||
| Total current assets | 1,861,391 | (25,166) | 1,836,225 | ||||||||||||||
| Property, plant and equipment, net | 450,870 | (14,043) | (a) | 436,827 | |||||||||||||
| Operating lease right-of-use assets, net | 146,823 | (2,755) | (a) | 144,068 | |||||||||||||
| Intangible assets, net | 2,137,551 | (122,594) | (a) | 2,014,957 | |||||||||||||
| Goodwill | 6,588,150 | (30,000) | (a) | 6,558,150 | |||||||||||||
| Other assets, net | 305,561 | 40,881 | (a), (b) | 346,442 | |||||||||||||
| Total assets | $ | 11,490,346 | $ | (153,677) | (a) | $ | 11,336,669 | ||||||||||
| Current liabilities: | |||||||||||||||||
| Current portion of long-term debt | $ | — | $ | — | $ | — | |||||||||||
| Accounts payable | 163,271 | (4,418) | (a) | 158,853 | |||||||||||||
| Accrued expenses and other current liabilities | 538,206 | 2,378 | (a) | 540,584 | |||||||||||||
| Total current liabilities | 701,477 | (2,040) | 699,437 | ||||||||||||||
| Long-term debt | 2,634,062 | $ | — | 2,634,062 | |||||||||||||
| Long-term liabilities | 752,731 | (32,086) | (a), (b) | 720,645 | |||||||||||||
| Operating lease liabilities | 130,970 | (1,707) | (a) | 129,263 | |||||||||||||
| Total liabilities | 4,219,240 | (35,833) | 4,183,407 | ||||||||||||||
| Total stockholders' equity | 7,271,106 | (117,844) | (a), (b) | 7,153,262 | |||||||||||||
| Total liabilities and stockholders' equity | $ | 11,490,346 | $ | (153,677) | $ | 11,336,669 | |||||||||||
| PREPARED IN ACCORDANCE WITH GAAP | |||||||||||||||||
Revvity, Inc. and Subsidiaries
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENTS
| Nine Months Ended October 4, 2026 | Nine Months Ended September 28, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| (In thousands, except per share data) | Historical | Disposition and Pro Forma Adjustments | Pro Forma | Historical | Disposition and Pro Forma Adjustments | Pro Forma | |||||||||||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 2,169,705 | $ | (62,078) | (c) | $ | 2,107,627 | $ | 2,083,995 | $ | (114,299) | (c) | $ | 1,969,696 | |||||||||||||||||||||||||||||||||||||||
| Cost of revenue | 946,605 | (33,312) | (c) | 913,293 | 941,289 | (61,004) | (c) | 880,285 | |||||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | 807,788 | (42,839) | (c) | 764,949 | 740,156 | 9,655 | (c), (d) | 749,811 | |||||||||||||||||||||||||||||||||||||||||||||
| Research and development expenses | 154,969 | (983) | 153,986 | 157,664 | — | 157,664 | |||||||||||||||||||||||||||||||||||||||||||||||
| Operating income from continuing operations | 260,343 | 15,056 | 275,399 | 244,886 | (62,950) | 181,936 | |||||||||||||||||||||||||||||||||||||||||||||||
| Interest income | (15,108) | 40 | (c) | (15,068) | (25,351) | 47 | (c) | (25,304) | |||||||||||||||||||||||||||||||||||||||||||||
| Interest expense | 68,521 | — | 68,521 | 68,672 | — | 68,672 | |||||||||||||||||||||||||||||||||||||||||||||||
| Change in fair value of investments | 7,828 | — | 7,828 | 3,484 | — | 3,484 | |||||||||||||||||||||||||||||||||||||||||||||||
| Other expense, net | 7,896 | 2,393 | (c) | 10,289 | 21,364 | (1,980) | (c) | 19,384 | |||||||||||||||||||||||||||||||||||||||||||||
| Income from continuing operations, before income taxes | 191,206 | 12,623 | 203,829 | 176,717 | (61,017) | 115,700 | |||||||||||||||||||||||||||||||||||||||||||||||
| Provision for income taxes | 34,211 | (1,529) | (c) | 32,682 | 32,605 | (2,367) | (c), (d) | 30,238 | |||||||||||||||||||||||||||||||||||||||||||||
| Income from continuing operations | 156,995 | 14,152 | 171,147 | 144,112 | (58,650) | 85,462 | |||||||||||||||||||||||||||||||||||||||||||||||
| Loss from discontinued operations | (2,158) | — | (2,158) | (1,275) | — | (1,275) | |||||||||||||||||||||||||||||||||||||||||||||||
| Net income | $ | 154,837 | $ | 14,152 | $ | 168,989 | $ | 142,837 | $ | (58,650) | $ | 84,187 | |||||||||||||||||||||||||||||||||||||||||
| Diluted earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income from continuing operations | $ | 1.40 | $ | 1.53 | $ | 1.22 | $ | 0.73 | |||||||||||||||||||||||||||||||||||||||||||||
| Loss from discontinued operations | (0.02) | (0.02) | (0.01) | (0.01) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | $ | 1.38 | $ | 1.51 | $ | 1.21 | $ | 0.72 | |||||||||||||||||||||||||||||||||||||||||||||
| Weighted average diluted shares of common stock outstanding | 111,764 | 111,764 | 117,735 | 117,735 | |||||||||||||||||||||||||||||||||||||||||||||||||
| ABOVE PREPARED IN ACCORDANCE WITH GAAP | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Revvity, Inc. and Subsidiaries
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENTS
| Twelve Months Ended December 28, 2025 | |||||||||||||||||||||||||||||||||||
| (In thousands, except per share data) | Historical | Disposition and Pro Forma Adjustments | Pro Forma | ||||||||||||||||||||||||||||||||
| Revenue | $ | 2,856,051 | $ | (164,552) | (c) | $ | 2,691,499 | ||||||||||||||||||||||||||||
| Cost of revenue | 1,291,686 | (99,558) | (c) | 1,192,128 | |||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | 991,890 | (14,122) | (c), (d) | 977,768 | |||||||||||||||||||||||||||||||
| Research and development expenses | 215,840 | — | 215,840 | ||||||||||||||||||||||||||||||||
| Operating income from continuing operations | 356,635 | (50,872) | 305,763 | ||||||||||||||||||||||||||||||||
| Interest income | (31,103) | 76 | (c) | (31,027) | |||||||||||||||||||||||||||||||
| Interest expense | 92,185 | — | 92,185 | ||||||||||||||||||||||||||||||||
| Change in fair value of investments | 11,456 | — | 11,456 | ||||||||||||||||||||||||||||||||
| Other expense, net | 15,820 | (2,765) | (c) | 13,055 | |||||||||||||||||||||||||||||||
| Income from continuing operations, before income taxes | 268,277 | (48,183) | 220,094 | ||||||||||||||||||||||||||||||||
| Provision for income taxes | 28,394 | 2,307 | (c), (d) | 30,701 | |||||||||||||||||||||||||||||||
| Income from continuing operations | 239,883 | (50,490) | 189,393 | ||||||||||||||||||||||||||||||||
| Income from discontinued operations | 1,318 | — | 1,318 | ||||||||||||||||||||||||||||||||
| Net income | $ | 241,201 | $ | (50,490) | $ | 190,711 | |||||||||||||||||||||||||||||
| Diluted earnings per share: | |||||||||||||||||||||||||||||||||||
| Income from continuing operations | $ | 2.06 | $ | 1.62 | |||||||||||||||||||||||||||||||
| Income from discontinued operations | 0.01 | 0.01 | |||||||||||||||||||||||||||||||||
| Net income | $ | 2.07 | $ | 1.63 | |||||||||||||||||||||||||||||||
| Weighted average diluted shares of common stock outstanding | 116,595 | 116,595 | |||||||||||||||||||||||||||||||||
| ABOVE PREPARED IN ACCORDANCE WITH GAAP | |||||||||||||||||||||||||||||||||||
Revvity, Inc. and Subsidiaries
NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1.Pro Forma Adjustments
(a) To eliminate all historical assets and liabilities of China IDX.
(b) To reflect a potential consideration from the sale of China IDX of $120 million, which includes certain liabilities to be transferred and excludes certain contingent consideration.
(c) To eliminate the historical revenues and expenses of China IDX.
(d) Includes the loss on the probable disposition of China IDX of $55 million, including tax impacts.